Skip to main content

Table 1 Characteristics of the 15 patients with MTX-LPD

From: The usefulness of 18F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD)

No Age range Underlying disease Length of MTX (mo) Final dose (mg/wk) sIL-2R (U/ml) LDH (U/L) PS Histological type EBV infection Stage IPI Prognosis
1 70s RA 48 8 259 212 0 FL - I 1 non-CR
2 70s RA 138 6 5861 190 3 DLBCL - IV 4 non-CR
3 60s RA 234 8 3744 292 3 - + III 4 non-CR
4 70s RA 103 6 310 241 1 MALT lymphoma N/A II 2 CR
5 60s PN 40 15 670 254 1 DLBCL + IV 4 non-CR
6 50s PA 83 10 3157 336 2 - + IV 3 CR
7 50s RA 101 10 737 229 0 polymorphic BLPD - III 1 non-CR
8 70s RA 50 8 864 209 1 polymorphic BLPD + IV 3 CR
9 70s RA 13 4 503 221 1 DLBCL - IE 1 CR
10 40s RA 7 8 758 149 0 - N/A II 0 CR
11 50s RA 48 6 340 176 1 polymorphic BLPD + IIE 0 CR
12 40s RA 48 16 1370 192 1 - - III 1 CR
13 60s RA 116 8 1136 242 1 DLBCL - IV 3 CR
14 50s RA 60 16 852 231 1 MZL + IV 3 non-CR
15 60s RA 172 8 402 252 0 DLBCL + IV 4 CR
  1. BLPD B-cell lymphoproliferative disease, CR complete response, DLBCL diffuse large B-cell lymphoma, EBV Epstein-Barr virus, F female, FL follicular lymphoma, IPI International Prognosis Index, LDH lactate dehydrogenase, M male, MTX methotrexate, MZL marginal zone lymphoma, N/A not available, PA psoriatic arthritis, PN polyarteritis nodosa, PS performance status, sIL-2R soluble interleukin-2 receptor